Please assess the completion status of the following clinical trial:

Trial Title: Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of allergic reactivity to cats as expressed by allergic rhinitis~* Radioallergosorbent test (RAST test) for cat-specific IgE with RAST rating of 2 (0.70-3.49 KU/L IgE) documented within the past year or at screening~* Standardized cat hair allergenic extract (CAT), 10,000 BAL/mL (ALK-Abello) elicits a wheal 5 mm or greater than the diluent control (Saline Albumin with Phenol \[HSA\], ALK-Abello) with surrounding erythema on testing using a standardized epicutaneous delivery device (Stallergenes Prick Lancet, 1 mm tip)~* Histamine (Histatrol 1mg/mL, ALK-Abello) reactivity of 5 mm or greater reactivity than the diluent control with surrounding erythema on epicutaneous testing using a standardized epicutaneous delivery device~* Able and willing to discontinue any anti-histamine use for 5 days prior to entry into protocol and throughout the protocol participation~* Baseline spirometry (FEV1, FVC FEF25-75) with FEV1 \>=80% predicted and other values within the normal range~* Ability to give written informed consent~Exclusion Criteria:~* Diluent control (Saline Albumin with Phenol \[HSA\], ALK-Abello) elicits wheal \>= 3 mm on epicutaneous testing using a standardized epicutaneous delivery device~* Pregnant females as determined by a positive serum or urine hCG test~* Lactating females~* Ever having received allergen immunotherapy (e.g., -subcutaneous allergen \[SCIT\] or -sublingual \[SLIT\])~* Systemic steroids in the past 3 months~* Severe systemic reactivity on exposure to cats (e.g., laryngeal or angioedema, fainting, pallor, bradycardia, hypotension, bronchospasm, asthma, or generalized urticaria)~* A clinical history of asthma~* Underlying heart, liver, kidney lung, or other medical condition (acute infections, immune diseases, current substance abuse) such that the person would be at a clearly increased risk for a poor outcome should a generalized allergic reaction occur~* Use of systemic beta-blocking or ACE-inhibiting agents within the past 3 weeks~* Use of tri-cyclic antidepressants within the past 3 weeks~* Subjects receiving therapy with any agents known or likely to interact with adrenaline (e.g., beta blockers, ACE-Inhibitors, tri-cyclic antidepressants, or other)~* Current use or use of omalizumab (Xolair) within past 6 months~* Subjects with any extensive skin disorder (atopic dermatitis) that would make skin testing or proper interpretation impractical~* Mental impairment, limiting the ability to comply with study requirements~* Participation in a clinical trial and receipt of an investigational product within 30 days, 5 half-lives or twice the duration of the biochemical effect of the investigational product (whichever is longer) prior to dosing in the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control-Experimental arm (Type: EXPERIMENTAL): Each subject will serve as their own control with the left arm receiving the control protein (Histamine prick, intradermal diluent and intradermal CAT) and right arm receiving the experimental protein (GFD).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy